Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2017 April;65(2) > Minerva Cardioangiologica 2017 April;65(2):173-8

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

REVIEW  


Minerva Cardioangiologica 2017 April;65(2):173-8

DOI: 10.23736/S0026-4725.16.04266-3

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current aspects of pulmonary arterial hypertension and therapeutics

Xianchi LI, Yuanyuang LIU, Peiying ZHANG

Xuzhou Central Hospital, Xuzhou, China


PDF  


The pulmonary arterial hypertension (PAH) patients have high rate of mortality due to right ventricle (or ventricular) (RV) failures. A lot of research work is being carried out in the area, however no treatment is available that could contrast the rise in mortality rates in PAH patients. β1-adrenoceptor blockers (β-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. Recent studies suggest β-blockers might be beneficial in PAH; however the mechanisms remain unknown. The present review article would put light on all these aspects of PAH along with latest ways for the management of PAH.


KEY WORDS: Hypertension, pulmonary - Therapeutics - Adrenergic beta-antagonists

inizio pagina

Publication History

Issue published online: January 3, 2017
Article first published online: November 23, 2016
Manuscript accepted: November 4, 2016
Manuscript received: October 25, 2016

Per citare questo articolo

Li X, Liu, Y Zhang P. Current aspects of pulmonary arterial hypertension and therapeutics. Minerva Cardioangiol 2017;65:173-8. DOI: 10.23736/S0026-4725.16.04266-3

Corresponding author e-mail

cx07782434@163.com